Back to Stakeholders
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchUniversities and Colleges with Dedicated Psychedelic Research Groups
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & Manufacturing

Massachusetts General Hospital

United States
18 Trials1 Paper

The Center for the Neuroscience of Psychedelics aims to better understand how psychedelics can be used to improve the treatment of mental illnesses. The core mission of the center is to understand exactly how psychedelics enhance the brain's capacity for change—or neuroplasticity—to optimize current treatments and render the term treatment resistant obsolete.

Academic Research

1 papers

Published Papers

1

Trial Involvement

18

Distinct Focus Topics

0

Latest Publication

Feb 13, 2026

Quick Facts

Type
hospital
HQ
United States
Website
Visit

Sponsored Trials

13
Not yet recruitingI

Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome

Start Date
Compounds
Ketamine
RecruitingIV

Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression

Start Date
Compounds
Ketamine, Esketamine
WithdrawnII

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

Start Date
Compounds
Psilocybin
TerminatedIV

N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

Start Date
Compounds
Ketamine, Placebo
CompletedIV

A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)

Start Date
Compounds
Ketamine, Placebo
WithdrawnIII

The Impact of Ketamine on the Reward Circuitry of Suicidal Patients

Start Date
Compounds
Ketamine
TerminatedNA

Physiological and Cognitive Biomarkers for Ketamine’s Antidepressant Effects

Start Date
Compounds
Ketamine
CompletedIV

Ketamine for Depression: An MRI Study

Start Date
Compounds
Ketamine
WithdrawnNA

Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder

Start Date
Compounds
Ketamine, Placebo
WithdrawnIV

Intranasal Ketamine for Late-Life Depression and Suicidal Ideation

Start Date
Compounds
Ketamine, Placebo
CompletedII

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

Start Date
Compounds
Ketamine, Placebo
CompletedNA

Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

Start Date
Compounds
Ketamine, Placebo
CompletedNA

Ketamine Infusion for Treatment-resistant Major Depressive Disorder

Start Date
Compounds
Ketamine

Collaborated Trials

5
RecruitingIII

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

Start Date
Compounds
Placebo, Ketamine
Enrolling by invitationIV

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan (REaKT-SD)

Start Date
Compounds
Ketamine, Placebo
RecruitingIII

Ketamine Treatment of Youth Suicide Attempters

Start Date
Compounds
Ketamine, Placebo
RecruitingI, II

Psilocybin for Psychological and Existential Distress in Palliative Care

Start Date
Compounds
Psilocybin
CompletedII

Sequential Therapy for the Treatment of Severe Bipolar Depression

Start Date
Compounds
Ketamine, Placebo

Research Papers

1
Paywallmeta

Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones

This pooled analysis (s=9) examined how much session facilitators shape participants' acute subjective effects across psilocybin studies involving 298 participants and 60 facilitators, finding that facilitator influence was negligible in healthy volunteers (0.8% of variance) but clinically meaningful in patient samples (13.6%), comparable to or exceeding typical therapist effects seen in conventional psychotherapy.

Published
Journal
Psychiatry Research
Authors
Goldy, S. P., Sepeda, N. D., Hilbert, S. N., Bari, B. A., Garcia-Romeu, A., Gukasyan, N., Barrett, F. S., Yaden, D. B., Nayak, S. M.